ERBB3 and pancreatic neoplasm: Pertuzumab efficacy in pancreatic cancer cells was greatly increased when exogenous NRG1 was added as stimulator, thus demonstrating that ligand-induced HER2/HER3 dimers strongly affect the fate of pancreatic tumor cells.